Press Release Details

Nov 9, 2022

Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 9, 2022-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT.

A webcast of the presentation may be accessed in the Investors section of the Company’s website at A replay will be available on Concert’s website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib (CTP-543), a novel, deuterated, oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with alopecia areata, a serious autoimmune dermatological disease. The Company is also evaluating the use of deuruxolitinib in other indications and assessing a number of earlier-stage pipeline candidates. For more information, please visit or follow us on Twitter, Instagram or LinkedIn.

Justine Koenigsberg
(781) 674-5284

Source: Concert Pharmaceuticals

Back to Top